Issue #2: Orencia
Added February 1, 2006 to the
Drug Monographs
Abatacept (Orencia®)
Manufacturer: Bristol-Myers Squibb Company
FDA Approved Indications: To reduce signs and symptoms, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs, such as methotrexate or TNF antagonists. Abatacept may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists.
Manufacturer: Bristol-Myers Squibb Company
FDA Approved Indications: To reduce signs and symptoms, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs, such as methotrexate or TNF antagonists. Abatacept may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists.